Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 03/21/24 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
   |
182 |
| 03/21/24 | 8-K | Current report filing |
|
|
9 |
| 03/20/24 | 8-K | Current report filing |
|
|
7 |
| 03/04/24 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/04/24 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/04/24 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/04/24 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/04/24 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/04/24 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 02/14/24 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
9 |
